DaVita Inc. announced its financial and operating results for the fourth quarter ended December 31, 2024, reporting adjusted diluted earnings per share (EPS) of $2.24. This figure topped analysts' average estimates of $2.13 per share.
Total revenues for Q4 2024 reached $3.29 billion, marking a 4.7% increase year-over-year. For the full year 2024, total revenues were $12.82 billion, and adjusted operating income was $1.981 billion, landing in the top half of the company's guidance range.
U.S. dialysis treatments for the fourth quarter were 7.28 million, representing a per day decrease of 1.4% compared to the third quarter of 2024. Normalized non-acquired treatment growth was (0.3)% year-over-year, indicating ongoing volume challenges.
Patient care costs per treatment increased to $264.60, primarily driven by higher center closure costs, health benefit expenses, and pharmaceutical unit costs. DaVita incurred approximately $24.2 million in U.S. dialysis center closure charges during the quarter.
The company continued its share repurchase program, buying back 2.3 million shares for $367 million in Q4 2024 at an average price of $156.46 per share. Internationally, DaVita expanded its footprint by acquiring 55 centers and opening one, while closing five centers outside the United States during the quarter.
For the full year 2025, DaVita projected adjusted operating income of $2.01 billion to $2.16 billion and adjusted diluted EPS of $10.20 to $11.30. This EPS guidance was below analysts' average expectation of $11.24 per share, primarily due to anticipated rising patient care costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.